Bay 3401016

Phase 2

Bayer

Bay 3401016 is one of 10 therapeutic programs targeting Alport syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Alport SyndromeRecruiting

Alport SyndromePhase 2

Recruiting

Competition

Competitive Landscape

22 competitors in Alport Syndrome

#DrugCompanyPhaseTrials

Lescol

Glucophage

1 3

Reata

Biogen

Phase 3

1 4

Farxiga

AstraZeneca

Preclinical

1 5

Zemplar

AbbVie

Preclinical

1 6

ELX-02

EEloxx Pharmaceuticals, Inc.

Phase 2

1 7

Setanaxib

CCalliditas Therapeutics Suisse SA

Phase 2

1 8

Vonafexor

EEnyo Pharma

Phase 2

1 9

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 10

Bay 3401016

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Alport Syndrome

NCT07211685

Clinical

Trials by Indication[1]

Alport syndrome1 trial

A Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 2a Study With an Extension Phase to Evaluate the Efficacy and Safety of BAY 3401016 in Participants Aged 18 to 45 With Alport Syndrome

Recruiting· Bayer logo

Bayer·Phase 2·NCT07211685·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bay 3401016. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bay 3401016. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Bayer

Bay 3401016

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Alport syndrome1 trial

References

Drug Info

Quick Facts

Related News